Rein Therapeutics
RNTX
19 hedge funds and large institutions have $3.21M invested in Rein Therapeutics in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 15 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
28.33% more ownership
Funds ownership: 1.56% → 29.89% (+28%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
42% less funds holding
Funds holding: 33 → 19 (-14)
45% less capital invested
Capital invested by funds: $5.86M → $3.21M (-$2.64M)
87% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair & Company
Chicago,
Illinois
|
+$21.9K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$10.8K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$8.08K |
| 4 |
Renaissance Technologies
New York
|
+$3.46K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$1.12K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$88.8K |
| 2 |
Envestnet Asset Management
Chicago,
Illinois
|
-$38K |
| 3 |
PAM
PVG Asset Management
Golden,
Colorado
|
-$24.3K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$24K |
| 5 |
GPFA
Game Plan Financial Advisors
Westlake,
Ohio
|
-$21K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Mercer Global Advisors
Denver,
Colorado
| – | -$4K | -1,005 | Closed |
|
27
LPL Financial
San Diego,
California
| – | -$4K | -1,000 | Closed |
|
|
LSAG
28
Lake Street Advisors Group
Portsmouth,
New Hampshire
| – | -$3K | -825 | Closed |
|
29
Millennium Management
New York
| – | -$2K | -600 | Closed |
|
|
RWP
30
Ridgecrest Wealth Partners
Mill Valley,
California
| – | -$2K | -500 | Closed |
|
31
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$7 | +2 | New |
|
RNTX Hedge Fund Activity: Q4 2022 in Review
19 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q4 2022, worth a combined $3.21M — down 45% from $5.86M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of RNTX and 2 opened new positions — a net loss of 13 holders — while 5 trimmed existing stakes and 7 added.
The largest buyer was William Blair & Company, adding an estimated $21.9K. The largest seller was BVF Inc, cutting an estimated $88.8K.
- 19 institutional investors held Rein Therapeutics (RNTX) as of Q4 2022, down from 33 in Q3 2022.
- Funds reported $3.21M of Rein Therapeutics stock for Q4 2022, down 45% quarter-over-quarter.
- 2 funds opened new Rein Therapeutics positions in Q4 2022 and 15 closed out, a net change of -13 holders.
- The largest Rein Therapeutics buyer in Q4 2022 was William Blair & Company, an estimated $21.9K added.
- The largest Rein Therapeutics seller in Q4 2022 was BVF Inc, an estimated $88.8K sold.
Based on aggregated 13F filings for Q4 2022.